Avandia Lawsuit Heart Attack Attorney
Other Avandia News
GSK to Cut Jobs in Wake of Avandia Problems
Category: Other Avandia News
GlaxoSmithKline (GSK) has announced that they will be cutting jobs at its Zebulon, North Carolina manufacturing plant. The news comes in the wake of lower than expected profits for 2007. The company will forfeit $1.4 million in incentives by cutting jobs at the plant. The incentives were part of an agreement with the state to invest at least $92 million in the plant and create 200 jobs by 2009. The Zebulon plant, one GSK's largest, will no longer be filling vacancies will be letting contract and temporary workers go first. Layoffs may quickly follow. The plant is responsible for the packaging of Avandia and with the demand nearly cut in half over the past several months it is understandable that GSK cannot employ the same amount of people to perform only half of the work.
Continue reading "GSK to Cut Jobs in Wake of Avandia Problems"
Avandia Study Leaked Before Publication
Category: Other Avandia News
A Texas researcher has admitted that he leaked a copy of the now infamous New England Journal of Medicine article that tied Avandia to an elevated heart risks. Steven Haffner of the University of Texas Health Science Center at San Antonio conceded that he faxed a pre-publication copy of the report to GlaxoSmithKline (GSK), the makers of Avandia, 17 days before the article was published. Haffner claims that the act was gratuitous and that he received no compensation and was not persuaded in any way by GSK representatives to share the privileged information. Sen. Chuck Grassley is leading the investigation in to the incident.
Avandia Hit With Another Wrongful Death Suit
Category: Other Avandia News
On Monday of this week the family of now deceased Milagros Larosa, 65, filed a wrongful death lawsuit against GlaxoSmithKline, the makers of the once blockbuster Avandia. The lawsuit alleges that GlaxoSmithKline liable for the death of Larosa due to their negligence, fraud, breach of warranty, and a their failure to adequately warn about the risks associated with Avandia.
Continue reading "Avandia Hit With Another Wrongful Death Suit"
Avandia Linked to Bone Disease
Category: Other Avandia News
New studies have demonstrated a possible link between the popular diabetes medication Avandia and osteoporosis. Scientists say that in laboratory studies of mice, rosiglitazone, sold as Avandia, disrupts the balance between osteoclasts, cells that are constantly destroying bone, and osteoblasts, cells that continuously lay down new bone. This balance is necessary for healthy and strong bones.
Diabetes Suffers Get Good News
Category: Other Avandia News
This week diabetes patients received some refreshing news about new chemicals that may help control diabetes. With a summer full of controversy and warnings about the effects of Avandia this news must be music to the ears of diabetes suffers. Scientists at Sitris Pharmaceuticals in Massachusetts were able locate chemicals that mimic the effects of red wine. The key ingredient in red wine, resveratol, has been shown to protect against fatty diets and combat the aging process.
FDA Employee Wants Higher Standards New Drugs
Category: Other Avandia News
An FDA official has called for higher standards for new drugs in the wake of the Avandia controversy. Avandia has been linked to an increased risk of heart failure and heart attack by a New England Journal of Medicine article. The FDA responded to the alleged tie by placing the strongest warning available on Avandia, but allowed the drug to remain on the market.
Continue reading "FDA Employee Wants Higher Standards New Drugs"
GSK Tried to Silence Doctor
Category: Other Avandia News
The British drug manufacturer GlaxoSmithKline has been bombarded with recent claims that its once blockbuster type-2 diabetes medication, Avandia, causes heart attacks. Apparently they have been hearing this type of sentiment about Avandia for years now, they have just managed to keep the voices silent. In 1999 Dr. John Buse, head of the diabetes center at the University of North Carolina, began expressing his concerns about cardiovascular risks associated with Avandia. A U.S. Senate Finance Committee report has alleged that Glaxo made attempts to stifle his remarks through intimidation.
Glaxo CEO Says Avandia Can Rebound
Category: Other Avandia News
On Monday in a phone interview GlaxoSmithKline CEO Jean-Pierre Garnier said that he believes Avandia may not be as big of a disaster as everyone has made it out to be. It has been reported that the FDA is considering adding an additional black box warning and label changes to the drug in the near future. The once blockbuster medication's sales began to plummet after a May New England Journal of Medicine article linked the type-2 diabetes drug to a significant increased risk of heart attack, and there have been speculations of additional warning swirling since the first black box warning was added in July.
Senator Probes FDA About Closed Door Vote on Avandia
Category: Other Avandia News
Republican Senator Charles Grassley wrote a letter to the FDA questioning if the there had been an internal vote of FDA experts earlier this month in regards to removing Avandia from the market. The alleged vote took place on October 2 and was participated in by 15 members of the FDA's Drug Safety Oversight Board (DSOB) with the decision to keep Avandia on the market narrowly winning by an 8-7 vote. The FDA set up the DSOB after harsh criticism ensued from the way the agency handled the recall of Merck's Vioxx.
Continue reading "Senator Probes FDA About Closed Door Vote on Avandia"
Avandia Access Restricted by VA
Category: Other Avandia News
The Department of Veteran's Affairs, commonly called the VA, has removed Avandia from their list of covered medications and will not provide new Avandia prescriptions. The VA will allow patients already taking the drug to continue use. In the past year the VA issued over 1.38 million prescriptions for Avandia, and the new decision will make an extensive impact on this number. The decision will likely place a sizable blow on the already volatile Avandia market.
Europe Increases Avandia Warnings
Category: Other Avandia News
Today the European Medicines Agency recommended tighter warnings to be placed on the type-2 diabetes medication Avandia. The agency did stand behind the drug saying that the benefits of the drug do outweigh the risks, and it will remain on the market. The UK based manufacturer, GlaxoSmithKline, has been under fire since Avandia was cited in May study to increase the risk of heart attack in recipients.
New Captain at the Helm for Avandia Makers
Category: Other Avandia News
Europe's largest drug company, GlaxoSmithKline, has announced that 43 year-old Andrew Witty will succeed chief executive Jean-Pierre Garnier in May. The decision was actually made at the end of last week when Witty was selected by the board of directors. Witty will have his hands full, with stock prices on the downslide and constant controversy surrounding the once blockbuster drug, Avandia. It will be under Witty's watch that the company will either continue to fall or be pulled back to its elite status.
Continue reading "New Captain at the Helm for Avandia Makers"
Pension Fund Takes Lead in Avandia Trial
Category: Other Avandia News
Over the weekend the Avon Pension Fund was appointed to be the lead plaintiff in a class-action lawsuit against GlaxoSmithKline. The UK based pension fund alleges that they were mislead by the pharmaceutical giant that failed to inform them of the heart attack risks associated with the type-2 diabetes medication Avandia.
Green Tea as Diabetes Treatment?
Category: Other Avandia News
With all of the controversy surrounding prescription diabetes medications like Avandia, diabetics are exploring alternative treatment methods and a new study out of Sweden claims that green tea may be a viable alternative to Avandia. Green Tea contains an antioxidant called epigallocatechin gallate (EGCG) that some claim to be as effective as Avandia in controlling blood sugar levels in patients with moderate diabetes.
In wake of Avandia FDA gets an Upgrade
Category: Other Avandia News
The type-2 diabetes medication Avandia has been surrounded by controversy in recent months after studies showed a significant increase heart failure risk amongst users. The controversy has put the FDA under the proverbial microscope as well. The recall of Vioxx a few years ago gave the FDA a bad image and recent claims against drugs like Paxil and of course Avandia have reignited the fire. It now appears that the FDA will be getting a much-needed overhaul in the coming months.
Researcher Reignites the FDA Approval Debate
Category: Other Avandia News
Dr. Clifford J. Rosen has added new fuel to the fire surrounding FDA drug approval and their less than perfect record in the recent years. He advises that the FDA should require greater proof of a effectiveness and have more in depth studies involving side effects before approving drugs.
Continue reading "Researcher Reignites the FDA Approval Debate"
Avandia Manufacturer Still Flying High on Stock Market
Category: Other Avandia News
The manufacturer of the diabetes medication Avandia, GlaxoSmithKline, has not been hit that hard in the stock market even with all of the negative publicity surrounding the type-2 diabetes drug. Experts say that even if the company were to lose all of its Avandia sales the stock would only see a six percent drop. This can be achieved through the diversity that big pharmaceutical companies have and the outrageous profits that these companies are seeing.
Continue reading "Avandia Manufacturer Still Flying High on Stock Market"
FDA Learns Lessons From Past Mistakes
Category: Other Avandia News
Over the past few years the Food and Drug Administration (FDA) has been under fire for approving drugs prematurely. In the case of Avandia, a type-2 diabetes medication, the FDA was pressured by the industry to approve the so-called "wonder drug" and this resulted in putting the end recipient at greater risk.
MedPage Today Avandia Poll Results
Category: Other Avandia News
A MedPage Today poll discovered only 9% of the poll respondents will continue prescribing Avandia (rosiglitazone) without concern and reservation. In fact, one in four believe it should be pulled from the market.
Avandia Users to be Assessed in New Study
Category: Other Avandia News
It was recently announced that health care provider Humana, will teaming up with the Miller Scholl of Medicine at the University of Miami, to conduct a study on improving drug safety. The 11.3 million member health care group will provide a their database to track possible dangers subsequent to a drug's release into the market. The study will include 41,000 diabetes patients, many of them Avandia users, who will be evaluated in conjunction with the recent connections of Avandia and cardiovascular risks.
Continue reading "Avandia Users to be Assessed in New Study"
Europe Reevaluates Avandia
Category: Other Avandia News
The popular diabetes medication Avandia is currently being evaluted by the IMB, the Irish Medicines Board. This current evaluation is scheduled to be completed sometime in October. The United States has recently released the news that the medication will now carry a "black box" label, due to the apparent relationship to an increase in heart failure amongst its users.
Class Action Lawsuit Against Maker of Avandia
Category: Other Avandia News
A class action lawsuit has been filed against GlaxoSmithKline, the makers of the diabetes drug, Avandia. The suit alleges users were not sufficiently warned about potential risks associated with taking the drug.
Continue reading "Class Action Lawsuit Against Maker of Avandia"
FDA to Ask Panel if Avandia Should be Pulled
Category: Other Avandia News
A summary released, Thursday said, the U.S. Food and Drug Administration (FDA) plans to ask outside experts if GlaxoSmithKline's drug, Avandia, should be pulled off the market or remain but with new stricter warning labels.
Continue reading "FDA to Ask Panel if Avandia Should be Pulled"
Avandia Prescriptions Declining
Category: Other Avandia News
Avandia prescriptions have declined approximately 10% since The New England Journal of Medicine posted a study that suggests the drug increases the patient's risk of heart attack, GlaxoSmithKline said.
Avandia Maker Sued
Category: Other Avandia News
The widow and son of a Beaumont man are suing the maker of the popular diabetes drug Avandia, claiming it contributed to the man's death from a heart attack.
Investor Lawsuit Alleges Glaxo Mislead on Avandia Risks
Category: Other Avandia News
GlaxoSmithKline is facing a lawsuit by investors who claim the drug maker misled shareholders about the safety of the diabetes drug Avandia.
Continue reading "Investor Lawsuit Alleges Glaxo Mislead on Avandia Risks"
New study on Avandia
Category: Other Avandia News
Avandia is the brand name for an anti-diabetic drug marketed by GlaxoSmithKline. It was approved by the FDA in 1999 and millions of Americans with diabetes take the drug to help control their blood sugar levels.
Avandia Prescriptions Declining
Category: Other Avandia News
During the first two days following a study that linked the type 2 diabetes drug Avandia to an increased risk of heart attack, physicians are shying away from prescribing it.
Avandia Increases Heart Attack Risk
Category: Other Avandia News
In February 2007, GlaxoSmithKline, released a press release that noted a greater increase of fractures in the upper arms, hands and feet of female diabetics that are taking Avandia, compared to those taking other diabetic medication. The information was discovered in data from an ADOPT trial.